Back to Results
First PageMeta Content
Health / AstraZeneca / Microbiology / Influenza vaccines / MF59 / Novartis / Influenza / FluMist / Avian influenza / Vaccination / Medicine / Vaccines


Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com
Add to Reading List

Document Date: 2014-01-31 11:39:08

Open Document

File Size: 184,48 KB

Share Result on Facebook

City

Develop Cell / Basel / /

Company

Novartis International AG / Novartis Group / Novartis AG / Twitter / /

Continent

North America / /

Country

Germany / Switzerland / United States / China / /

Currency

USD / /

/

Event

Earnings Announcement / FDA Phase / /

Facility

Craig Venter Institute / /

IndustryTerm

protective solution / production technologies / cell culture technology / over-the-counter and animal health products / generic pharmaceuticals / cell-culture manufacturing technology / diagnostic tools / healthcare solutions / produced utilizing full-scale cell-culture manufacturing technology / /

MedicalCondition

Novartis H7N9 avian influenza / H7N9 avian influenza virus / immunogenic trivalent subunit influenza / H7N9 infection / /

Organization

U.S. Department of Health and Human Services / Craig Venter Institute / US Securities and Exchange Commission / Biomedical Advanced Research and Development Authority / FDA / /

Person

Stephen Rubino Jill Pozarek / Andrin Oswald / Liz Power Novartis Vaccines / Samir Shah Pierre-Michel Bringer / Thomas Hungerbuehler Isabella Zinck / /

/

Position

Division Head / Assistant Secretary for Preparedness and Response / /

Product

investigational cell culture vaccine / H7N9 / /

Technology

alternative technology / cell-culture manufacturing technology / egg-based methods.2 Cell-culture technology / production technologies / cell culture technology / /

URL

http /

SocialTag